)
Harrow (HROW) investor relations material
Harrow Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Financial performance and growth
Five-year revenue CAGR exceeded 40%; adjusted EBITDA CAGR exceeded 60%. FY2026 revenue guidance is $350M–$365M, midpoint $357.5M, vs. $272.3M in FY2025.
Q3 2026 was a record: revenue exceeded $99M, including $83.5M branded revenue at nearly 80% gross margin; cash was ~$75M at quarter-end.
Q4 2026 adjusted EBITDA guidance exceeded $33M, vs. $21.2M recently reported; $300M unsecured notes carry an 8.625% coupon and mature in about four years.
Core brands
VEVYE generated nearly $40M in Q3 2026 revenue, up 75% YoY; prescriptions rose 83% YoY and revenue increased 35% QoQ. IP extends to 2039.
VEVYE is a water-free cyclosporine formulation delivering ~22x more cyclosporine to the inflammation site than the vehicle in RESTASIS; 10.7M new commercial lives are expected to become accessible Jan. 1.
IHEEZO generated >$25M in Q3 2026 revenue, up 15%; unit demand rose 21% YoY despite losing cataract-surgery pass-through status at end-Q1. Net price rose 25% July 1.
Management expects Q4 2026 to be IHEEZO's strongest quarter to date; QUELL data showed less pain, ocular surface damage and adverse events 4–24 hours after topical anesthesia vs. injected lidocaine.
TRIESENCE revenue exceeded $10M in Q3 2026, up 186%, with unit demand up 110%; coverage exceeds 95% and patient out-of-pocket cost is ~$38.
Operating leverage
SG&A was 84% of revenue in H1 2026 and 54% in Q3; Q3 revenue rose 41% while SG&A was flat QoQ.
Of the ~$28M Q2-to-Q3 revenue increase, $22M flowed to profit, a 78% conversion; management expects costs to grow more slowly than revenue in coming quarters.
- Record branded-led Q3 growth; FY revenue held, but Adjusted EBITDA outlook reset above $40M.HROW
Q3 2026 - Long-term strategy targets $250M quarterly revenue by 2027, driven by G-MELT, IHEEZO, and VEVYE.HROW
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 revenue grew 11% YoY to $70.7M, with guidance reaffirmed and TYRVAYA acquisition announced.HROW
Q2 2026 - Accelerating growth driven by innovative eye care products and strong 2026 financial outlook.HROW
46th Annual William Blair Growth Stock Conference - Q1 2026 revenue was $44.2M, with strong product growth and improved liquidity.HROW
Q1 2026 - Key votes on directors, executive pay, and auditor set for June 2026 annual meeting.HROW
Proxy filing - Proxy covers director elections, say-on-pay, auditor ratification, and strong governance practices.HROW
Proxy filing - Double-digit growth and expanding ophthalmic launches drive strong future outlook.HROW
Leerink Global Healthcare Conference 2026 - Targets $250M+ quarterly revenue by Q4 2027, led by new launches and expanded access.HROW
Investor Day 2025
)
)
)
)
)
)
)
)